ALX Oncology reports Q4 2021 net loss $28.4M ($0.70/shr); cash $363.7M through mid-2024

ALX ONCOLOGY HOLDINGS INC

2022-FY EPS reported -$2.07

GAAP net loss Q4 2021: $28.4M ($0.70/shr) vs $18.8M ($0.50/shr) year ago; full year loss $83.5M ($2.07/shr).
R&D expenses Q4 $20.9M (incl. $4.7M ScalmiBio acquisition IPR&D) vs $12.1M year ago.
Cash $363.7M at Dec 31, 2021; runway through mid-2024.
FDA granted Orphan Drug Designation for evorpacept in gastric/GEJ cancer (Jan 2022).
Plan to initiate randomized Phase 2/3 ASPEN-06 trial in 2nd line gastric/GEJ cancer in 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.